HC-gp39和GP73检测对原发性肝癌的诊断及TACE预后的评估价值  

Value of HC-gp39 and GP73 in the diagnosis of primary liver cancer and prognosis of TACE

作　　者：唐辉 刘伟[1] 陈根生 Hui Tang;Wei Liu;Gen-sheng Chen(Department of Intervention,Lishui People's Hospital,Lishui,Zhejiang 323000,China)

机构地区：[1]丽水市人民医院介入科,浙江丽水323000

出　　处：《中国现代医学杂志》2020年第10期54-58,共5页China Journal of Modern Medicine

摘　　要：目的探讨血清人软骨糖蛋白39(HC-gp39)和高尔基体糖蛋白73(GP73)检测对原发性肝癌(PHC)的诊断及经导管肝动脉化疗栓塞术(TACE)预后的评估价值。方法选取2016年6月-2018年6月丽水市人民医院收治的PHC患者58例作为观察组,同期该院健康体检者60例作为对照组。检测两组血清HC-gp39、GP73水平,采用受试者工作特征(ROC)曲线和生存曲线分析HC-gp39、GP73在PHC患者TACE预后中的评估价值。结果观察组治疗前、治疗后1个月血清HC-gp39、GP73水平均高于对照组(P<0.05),且观察组治疗后1个月低于治疗前(P<0.05)。血清HC-gp39、GP73联合诊断PHC的ROC曲线下面积(AUC)为0.814(95%CI:0.733,0.892),敏感性和特异性分别为70.0%(95%CI:0.636,0.766)和88.6%(95%CI:0.822,0.969)。治疗后血清HC-gp39<335.76 pg/ml患者总体生存率(33.33%)高于血清HC-gp39≥335.76 pg/ml患者(25.00%)(P<0.05);治疗后血清HC-gp39<335.76 pg/ml患者中位生存时间(25.50个月)高于血清HC-gp39≥335.76 pg/ml患者(20.86个月)(P<0.05)。治疗后血清GP73<213.84 ng/ml患者总体生存率(38.71%)高于血清GP73≥213.84 ng/ml患者(25.00%)(P<0.05);治疗后血清GP73<213.84 ng/ml患者中位生存时间(24.63个月)高于血清GP73≥213.84 ng/ml患者(20.12个月)(P<0.05)。结论血清HC-gp39、GP73水平升高对PHC具有一定诊断价值,联合诊断价值更高。TACE术后血清HC-gp39、GP73水平降低PHC患者的生存质量明显优于未降低患者,两者对TACE术后预后具有一定评估价值。Objective To investigate the value of serum human cartilage glycoprotein 39(HC-gp39)and Golgi protein 73(GP73)in diagnosis of primary liver cancer and prognosis of transcatheter arterial chemoembolization(TACE).Methods Total of 58 patients with primary liver cancer admitted to our hospital from June 2016 to June 2018 were selected as the observation group,and 60 healthy patients during the same period were selected as the control group.The levels of serum HC-gp39 and GP73 in the two groups were detected.The receiver operating characteristic curve(ROC)and the survival curve were used to analyze the diagnostic value of HC-gp39 and GP73 in primary liver cancer and the prognosis of TACE.Results The levels of serum HC-gp39 and GP73 in the observation group were higher than those in the control group before treatment(P<0.05).1 month after treatment,the levels of serum HC-gp39 and GP73 in the observation group were lower than those before treatment and higher than those in the control group(P<0.05).The AUC of serum HC-gp39 and GP73 combined in the diagnosis of primary liver cancer was 0.814(95%CI:0.733,0.892),and the sensitivity and specificity were 70.05%(95%CI:63.65%,76.55%)and 88.64%(95%CI:82.24%,96.94%)respectively.The overall survival of patients with serum HCgp39<335.76 pg/ml after treatment was 33.33%,higher than 25.00%of patients with serum HC-gp39≥335.76 pg/ml after treatment(χ~2=3.192,P=0.036).The median survival time of patients with serum HC-gp39<335.76 pg/ml after treatment was 25.50 months,higher than 20.86 months of patients with serum HC-gp39≥335.76 pg/ml after treatment(χ~2=5.145,P=0.020).The overall survival of patients with serum GP73<213.84 ng/ml after treatment was 38.71%,which was higher than 25.00%of patients with serum GP73≥213.84 ng/ml after treatment(χ~2=4.176,P=0.029).The median survival time of patients with serum GP73<213.84 ng/ml after treatment was 24.63 months,which was higher than 20.12 months of patients with serum GP73≥213.84 ng/ml after treatment(χ~2=4.996,P=0.025).Conclus

关 键 词：肝肿瘤 肿瘤 多原发性 糖蛋白类 抗肿瘤联合化疗方案 血清学试验 

分 类 号：R735.7[医药卫生—肿瘤]